The Weight of Misinformation: Novo Nordisk vs Eli Lilly in the Battle for Truth Novo Nordisk, a Danish pharmaceutical company, has filed a lawsuit against US rival Eli Lilly over what it claims are "false and materially misleading" advertising campaigns for its weight loss treatments Zepbound and Mounjaro.
According to Novo Nordisk, Eli Lilly cherry picked outdated studies that show its products performing better than those of its competitor, semaglutide.
The dispute centers on the use of selective presentation of data and omission of critical clinical context in Eli Lilly's advertising campaigns.